Please login to the form below

secukinumab

This page shows the latest secukinumab news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Latest news

AbbVie reports more solid data for would-be psoriasis blockbuster

Its profile could also help it make headway against other new psoriasis drugs, including IL-17 inhibitors such as Novartis’fast-growing Cosentyx (secukinumab) as well as Eli Lilly’s Taltz
Novartis negotiates ex-US rights to Spark gene therapy

The gains were driven by strong performances from new immunotherapy Cosentyx (secukinumab), which breached the $2bn sales threshold for the year, as well as heart failure therapy Entresto (sacubitril and valsartan)
Lilly claims another EU okay for Taltz

up in the market with Novartis’first-to-market IL-17 inhibitor Cosentyx (secukinumab) which was approved for psoriasis several months earlier and has since had its uses extended to include
Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

The two trials - SURPASS and EXCEED - will compare interleukin-17 antagonist Cosentyx (secukinumab) against TNF blocker adalimumab in ankylosing spondylitis and psoriatic arthritis, respectively.
Janssen’s Tremfya cleared for European use

secukinumab) in an already-crowded psoriasis market.

More from news
Approximately 16 fully matching, plus 56 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

multiple sclerosis and secukinumab for several inflammatory conditions.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Account Manager – Med Comms – Kent: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Scientific Director: Great salary and bebefits

Senior Programme Executive: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Subscribe to our email news alerts

PMHub

Add my company

Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...